Latest Pharma Insights
Osteoboost Raises $8M To Scale FDA-Cleared Vibration Device For Osteopenia
Osteoboost has raised $8m in a Series A-prime round to expand manufacturing and sales for its FDA-cleared vibration therapy device for postmenopausal women with osteopenia. CEO Laura Yecies said early demand has outpaced supply, but lack of reimbursement remains key hurdle.
Medtech Insight - April 15, 2026
Osteoboost has raised $8m in a Series A-prime round to expand manufacturing and sales for its FDA-cleared vibration therapy device for postmenopausal women with osteopenia. CEO Laura Yecies said early demand has outpaced supply, but lack of reimbursement remains key hurdle.
Medtech Insight - April 15, 2026
Unilever Continues Growing Nutrition Portfolio By Acquiring Grüns ‘Greens Supplement’ Firm
Deal is latest step in what Unilever says process of is reshaping its portfolio toward premium and high growth spaces, with a stronger focus on beauty and wellbeing and the US market.
HBW Insight - April 15, 2026
Deal is latest step in what Unilever says process of is reshaping its portfolio toward premium and high growth spaces, with a stronger focus on beauty and wellbeing and the US market.
HBW Insight - April 15, 2026
Jazz Talks Deals Amid Business Strategy Evolution
CFO Philip Johnson said the company is interested in bringing in more assets in new rare disease areas, particularly at proof-of-concept or later in development.
Scrip - April 15, 2026
CFO Philip Johnson said the company is interested in bringing in more assets in new rare disease areas, particularly at proof-of-concept or later in development.
Scrip - April 15, 2026
Revolution’s Strong Data Garner An Upsized Investor Response
Revolution Medicines sought $1bn from a follow-on offering, but ultimately grossed $2bn as investors sought to back the company after its positive Phase III pancreatic cancer readout.
Scrip - April 15, 2026
Revolution Medicines sought $1bn from a follow-on offering, but ultimately grossed $2bn as investors sought to back the company after its positive Phase III pancreatic cancer readout.
Scrip - April 15, 2026
Cardiovascular Leads J&J Medtech’s Q1 As Abiomed And Shockwave Deliver Double-Digit Growth
J&J's cardiovascular bet is paying off. Abiomed grew 14%, Shockwave 18%, and electrophysiology 9.5% in the first quarter – but tariffs cut medtech margins by 360 basis points. The robotic surgery question is next, with OTTAVA FDA approval expected before year-end.
Medtech Insight - April 15, 2026
J&J's cardiovascular bet is paying off. Abiomed grew 14%, Shockwave 18%, and electrophysiology 9.5% in the first quarter – but tariffs cut medtech margins by 360 basis points. The robotic surgery question is next, with OTTAVA FDA approval expected before year-end.
Medtech Insight - April 15, 2026
MedCon Preview: MDUFA, AI, QMSR, FDA Inspections On Tap For Columbus Conference
The upcoming MedCon conference in Columbus, Ohio, will offer stakeholders insights on several topics, including the latest updates on MDUFA negotiations, QMSR implementation, and the emergence of AI in medtech.
Medtech Insight - April 15, 2026
The upcoming MedCon conference in Columbus, Ohio, will offer stakeholders insights on several topics, including the latest updates on MDUFA negotiations, QMSR implementation, and the emergence of AI in medtech.
Medtech Insight - April 15, 2026
Biopharma Mid-Cap Investors On A Yo-Yo Diet In Q1
Erasca led a group of specialist oncology companies gaining ground in the first quarter of 2026, while companies developing novel obesity assets have experienced the downside of yo-yoing investor sentiment.
Scrip - April 15, 2026
Erasca led a group of specialist oncology companies gaining ground in the first quarter of 2026, while companies developing novel obesity assets have experienced the downside of yo-yoing investor sentiment.
Scrip - April 15, 2026
Healthtech Start-Ups Set The Tone At BioWales ’26
A “venture builder” in precision mental health biology, a company that has done the heavy lifting for a class III cardiac implantable and a diagnostics innovator addressing care shift realities long before the NHS’s 10-Year Plan was issued were among the start-ups seeking investors at BioWales 2026.
In Vivo - April 15, 2026
A “venture builder” in precision mental health biology, a company that has done the heavy lifting for a class III cardiac implantable and a diagnostics innovator addressing care shift realities long before the NHS’s 10-Year Plan was issued were among the start-ups seeking investors at BioWales 2026.
In Vivo - April 15, 2026
How An Italian Ocular AAV Innovator Is Bucking The Trend In Gene Therapy
AAVantgarde is advancing dual-AAV gene therapies for two inherited retinal diseases, using staged clinical de-risking to build investor and regulatory confidence ahead of key 2026 data readouts.
In Vivo - April 15, 2026
AAVantgarde is advancing dual-AAV gene therapies for two inherited retinal diseases, using staged clinical de-risking to build investor and regulatory confidence ahead of key 2026 data readouts.
In Vivo - April 15, 2026
Poolbeg Well Placed To Calm The Cytokine Storm
The firm is on track to deliver interim data this summer on its oral therapy to prevent cytokine release syndrome which could become a multi-billion dollar product.
Scrip - April 15, 2026
The firm is on track to deliver interim data this summer on its oral therapy to prevent cytokine release syndrome which could become a multi-billion dollar product.
Scrip - April 15, 2026
France’s Gemme Becomes ALMA
Becoming the latest industry association to adopt a new identity, French generics and biosimilars group Gemme has become ALMA: the alliance des médicaments abordables, or alliance for affordable medicines.
Generics Bulletin - April 15, 2026
Becoming the latest industry association to adopt a new identity, French generics and biosimilars group Gemme has become ALMA: the alliance des médicaments abordables, or alliance for affordable medicines.
Generics Bulletin - April 15, 2026
Mankind And Amneal Launch US Lumigan Generics Despite Valid Patent
AbbVie/Allergan’s Lumigan is now competing with two generic rivals in the US, even though the drug substance patent is still in force.
Generics Bulletin - April 15, 2026
AbbVie/Allergan’s Lumigan is now competing with two generic rivals in the US, even though the drug substance patent is still in force.
Generics Bulletin - April 15, 2026
Lupin Acquires VISUfarma To Grow OTC Ophthalmology Offering
Lupin has completed its €190m acquisition of VISUfarma, adding a 60-plus product ophthalmology portfolio which includes the Trehapan and Xailin OTC eye drop brands and dietary supplements CoQUN and VISUfly.
HBW Insight - April 15, 2026
Lupin has completed its €190m acquisition of VISUfarma, adding a 60-plus product ophthalmology portfolio which includes the Trehapan and Xailin OTC eye drop brands and dietary supplements CoQUN and VISUfly.
HBW Insight - April 15, 2026
Samsung Win Protects Early Foothold In US Ustekinumab Market
Samsung Bioepis can continue supplying its Sandoz-partnered ustekinumab biosimilar to Cigna’s Quallent after the Third Circuit denied Johnson & Johnson’s preliminary injunction bid, preserving a major US distribution channel while the underlying contract dispute proceeds.
Generics Bulletin - April 15, 2026
Samsung Bioepis can continue supplying its Sandoz-partnered ustekinumab biosimilar to Cigna’s Quallent after the Third Circuit denied Johnson & Johnson’s preliminary injunction bid, preserving a major US distribution channel while the underlying contract dispute proceeds.
Generics Bulletin - April 15, 2026
Study Validates Ebenbuild’s Lung ‘Digital Twin’ For Drug Intake. Next Up: Trials For Clinical Use
A new study validates Ebenbuild’s lung “digital twin” technology for predicting drug deposition, a key gap in respiratory medicine. The Munich-based company is also developing a device software product Aerogram to help clinicians optimize ventilation in intensive care patients.
Medtech Insight - April 15, 2026
A new study validates Ebenbuild’s lung “digital twin” technology for predicting drug deposition, a key gap in respiratory medicine. The Munich-based company is also developing a device software product Aerogram to help clinicians optimize ventilation in intensive care patients.
Medtech Insight - April 15, 2026
Rising Leaders: Helping AI Software Enter Healthcare Systems And Markets
Isabel Vincent, market development manager at life sciences software consultancy Firefinch, has seen an explosion in workload as healthcare organizations and healthtech innovators embed new functionalities into businesses processes. Away from that job, she finds time to advise and mentor start-ups.
In Vivo - April 15, 2026
Isabel Vincent, market development manager at life sciences software consultancy Firefinch, has seen an explosion in workload as healthcare organizations and healthtech innovators embed new functionalities into businesses processes. Away from that job, she finds time to advise and mentor start-ups.
In Vivo - April 15, 2026
BMS/Bain $300m Venture Emerges As Beeline With Lead Asset Nearing Pivotal Stage
Beeline Medicines was created to develop five Bristol Myers Squibb assets under an agreement in which Bain Capital and others committed $300m to a new company. Lead drug afimetoran is in Phase IIb for lupus.
Scrip - April 15, 2026
Beeline Medicines was created to develop five Bristol Myers Squibb assets under an agreement in which Bain Capital and others committed $300m to a new company. Lead drug afimetoran is in Phase IIb for lupus.
Scrip - April 15, 2026
Court Keeps Core Copaxone Claims Alive Against Teva
A US court has narrowed Mylan’s Copaxone antitrust case against Teva, dismissing several theories while allowing core claims on alleged exclusionary conduct, including marketing and rebate practices, to proceed under a broader monopolization framework.
Generics Bulletin - April 15, 2026
A US court has narrowed Mylan’s Copaxone antitrust case against Teva, dismissing several theories while allowing core claims on alleged exclusionary conduct, including marketing and rebate practices, to proceed under a broader monopolization framework.
Generics Bulletin - April 15, 2026
Japan’s Suntory Makes Major OTC Play With Daiichi Sankyo Deal
Suntory is significantly stepping up its presence in Japan's consumer health market with the acquisition of Daiichi Sankyo Healthcare, which operates in categories such as cold & flu, skin care and oral health.
HBW Insight - April 15, 2026
Suntory is significantly stepping up its presence in Japan's consumer health market with the acquisition of Daiichi Sankyo Healthcare, which operates in categories such as cold & flu, skin care and oral health.
HBW Insight - April 15, 2026
Daiichi Sankyo Tightens Oncology Focus Through OTC Divestment To Suntory
Daiichi Sankyo tightens strategic focus on innovative prescription drugs in oncology through divestment of its OTC subsidiary to Suntory, which gains cold, skincare and dental lines.
Scrip - April 15, 2026
Daiichi Sankyo tightens strategic focus on innovative prescription drugs in oncology through divestment of its OTC subsidiary to Suntory, which gains cold, skincare and dental lines.
Scrip - April 15, 2026
Alphamab’s Bispecific Phase III Win In Breast Cancer Lays Runway For Take Off
On the heels of Alphamab Oncology's anti-HER2 bispecific meeting its Phase III endpoint in early breast cancer, the Chinese firm's CEO shares pipeline development plans and R&D strategies.
Scrip - April 15, 2026
On the heels of Alphamab Oncology's anti-HER2 bispecific meeting its Phase III endpoint in early breast cancer, the Chinese firm's CEO shares pipeline development plans and R&D strategies.
Scrip - April 15, 2026
AZ Optimistic On Japan Prospects Despite Pricing, LoE Challenges
While AstraZeneca Japan's sales were flat last year, the UK firm's new country president sees a target of 50 new approvals/indications by 2030 as more than overcoming Forxiga's LoE and a big price cut for Imfinzi.
Scrip - April 15, 2026
While AstraZeneca Japan's sales were flat last year, the UK firm's new country president sees a target of 50 new approvals/indications by 2030 as more than overcoming Forxiga's LoE and a big price cut for Imfinzi.
Scrip - April 15, 2026
EU Beauty Industry Facing First Compliance Deadline For Allergen Labeling
Cosmetic products newly added to the EU market July 31 and afterward must follow the expanded fragrance allergen labeling requirements of Annex III of the EU Cosmetics Regulation.
HBW Insight - April 15, 2026
Cosmetic products newly added to the EU market July 31 and afterward must follow the expanded fragrance allergen labeling requirements of Annex III of the EU Cosmetics Regulation.
HBW Insight - April 15, 2026
Jazz Talks Deals Amid Business Strategy Evolution
CFO Philip Johnson said the company is interested in bringing in more assets in new rare disease areas, particularly at proof-of-concept or later in development.
Scrip - April 15, 2026
CFO Philip Johnson said the company is interested in bringing in more assets in new rare disease areas, particularly at proof-of-concept or later in development.
Scrip - April 15, 2026
Revolution’s Strong Data Garner An Upsized Investor Response
Revolution Medicines sought $1bn from a follow-on offering, but ultimately grossed $2bn as investors sought to back the company after its positive Phase III pancreatic cancer readout.
Scrip - April 15, 2026
Revolution Medicines sought $1bn from a follow-on offering, but ultimately grossed $2bn as investors sought to back the company after its positive Phase III pancreatic cancer readout.
Scrip - April 15, 2026
Biopharma Mid-Cap Investors On A Yo-Yo Diet In Q1
Erasca led a group of specialist oncology companies gaining ground in the first quarter of 2026, while companies developing novel obesity assets have experienced the downside of yo-yoing investor sentiment.
Scrip - April 15, 2026
Erasca led a group of specialist oncology companies gaining ground in the first quarter of 2026, while companies developing novel obesity assets have experienced the downside of yo-yoing investor sentiment.
Scrip - April 15, 2026
Poolbeg Well Placed To Calm The Cytokine Storm
The firm is on track to deliver interim data this summer on its oral therapy to prevent cytokine release syndrome which could become a multi-billion dollar product.
Scrip - April 15, 2026
The firm is on track to deliver interim data this summer on its oral therapy to prevent cytokine release syndrome which could become a multi-billion dollar product.
Scrip - April 15, 2026
BMS/Bain $300m Venture Emerges As Beeline With Lead Asset Nearing Pivotal Stage
Beeline Medicines was created to develop five Bristol Myers Squibb assets under an agreement in which Bain Capital and others committed $300m to a new company. Lead drug afimetoran is in Phase IIb for lupus.
Scrip - April 15, 2026
Beeline Medicines was created to develop five Bristol Myers Squibb assets under an agreement in which Bain Capital and others committed $300m to a new company. Lead drug afimetoran is in Phase IIb for lupus.
Scrip - April 15, 2026
Daiichi Sankyo Tightens Oncology Focus Through OTC Divestment To Suntory
Daiichi Sankyo tightens strategic focus on innovative prescription drugs in oncology through divestment of its OTC subsidiary to Suntory, which gains cold, skincare and dental lines.
Scrip - April 15, 2026
Daiichi Sankyo tightens strategic focus on innovative prescription drugs in oncology through divestment of its OTC subsidiary to Suntory, which gains cold, skincare and dental lines.
Scrip - April 15, 2026
Alphamab’s Bispecific Phase III Win In Breast Cancer Lays Runway For Take Off
On the heels of Alphamab Oncology's anti-HER2 bispecific meeting its Phase III endpoint in early breast cancer, the Chinese firm's CEO shares pipeline development plans and R&D strategies.
Scrip - April 15, 2026
On the heels of Alphamab Oncology's anti-HER2 bispecific meeting its Phase III endpoint in early breast cancer, the Chinese firm's CEO shares pipeline development plans and R&D strategies.
Scrip - April 15, 2026
AZ Optimistic On Japan Prospects Despite Pricing, LoE Challenges
While AstraZeneca Japan's sales were flat last year, the UK firm's new country president sees a target of 50 new approvals/indications by 2030 as more than overcoming Forxiga's LoE and a big price cut for Imfinzi.
Scrip - April 15, 2026
While AstraZeneca Japan's sales were flat last year, the UK firm's new country president sees a target of 50 new approvals/indications by 2030 as more than overcoming Forxiga's LoE and a big price cut for Imfinzi.
Scrip - April 15, 2026
Osteoboost Raises $8M To Scale FDA-Cleared Vibration Device For Osteopenia
Osteoboost has raised $8m in a Series A-prime round to expand manufacturing and sales for its FDA-cleared vibration therapy device for postmenopausal women with osteopenia. CEO Laura Yecies said early demand has outpaced supply, but lack of reimbursement remains key hurdle.
Medtech Insight - April 15, 2026
Osteoboost has raised $8m in a Series A-prime round to expand manufacturing and sales for its FDA-cleared vibration therapy device for postmenopausal women with osteopenia. CEO Laura Yecies said early demand has outpaced supply, but lack of reimbursement remains key hurdle.
Medtech Insight - April 15, 2026
Cardiovascular Leads J&J Medtech’s Q1 As Abiomed And Shockwave Deliver Double-Digit Growth
J&J's cardiovascular bet is paying off. Abiomed grew 14%, Shockwave 18%, and electrophysiology 9.5% in the first quarter – but tariffs cut medtech margins by 360 basis points. The robotic surgery question is next, with OTTAVA FDA approval expected before year-end.
Medtech Insight - April 15, 2026
J&J's cardiovascular bet is paying off. Abiomed grew 14%, Shockwave 18%, and electrophysiology 9.5% in the first quarter – but tariffs cut medtech margins by 360 basis points. The robotic surgery question is next, with OTTAVA FDA approval expected before year-end.
Medtech Insight - April 15, 2026
MedCon Preview: MDUFA, AI, QMSR, FDA Inspections On Tap For Columbus Conference
The upcoming MedCon conference in Columbus, Ohio, will offer stakeholders insights on several topics, including the latest updates on MDUFA negotiations, QMSR implementation, and the emergence of AI in medtech.
Medtech Insight - April 15, 2026
The upcoming MedCon conference in Columbus, Ohio, will offer stakeholders insights on several topics, including the latest updates on MDUFA negotiations, QMSR implementation, and the emergence of AI in medtech.
Medtech Insight - April 15, 2026
Study Validates Ebenbuild’s Lung ‘Digital Twin’ For Drug Intake. Next Up: Trials For Clinical Use
A new study validates Ebenbuild’s lung “digital twin” technology for predicting drug deposition, a key gap in respiratory medicine. The Munich-based company is also developing a device software product Aerogram to help clinicians optimize ventilation in intensive care patients.
Medtech Insight - April 15, 2026
A new study validates Ebenbuild’s lung “digital twin” technology for predicting drug deposition, a key gap in respiratory medicine. The Munich-based company is also developing a device software product Aerogram to help clinicians optimize ventilation in intensive care patients.
Medtech Insight - April 15, 2026
Unilever Continues Growing Nutrition Portfolio By Acquiring Grüns ‘Greens Supplement’ Firm
Deal is latest step in what Unilever says process of is reshaping its portfolio toward premium and high growth spaces, with a stronger focus on beauty and wellbeing and the US market.
HBW Insight - April 15, 2026
Deal is latest step in what Unilever says process of is reshaping its portfolio toward premium and high growth spaces, with a stronger focus on beauty and wellbeing and the US market.
HBW Insight - April 15, 2026
Lupin Acquires VISUfarma To Grow OTC Ophthalmology Offering
Lupin has completed its €190m acquisition of VISUfarma, adding a 60-plus product ophthalmology portfolio which includes the Trehapan and Xailin OTC eye drop brands and dietary supplements CoQUN and VISUfly.
HBW Insight - April 15, 2026
Lupin has completed its €190m acquisition of VISUfarma, adding a 60-plus product ophthalmology portfolio which includes the Trehapan and Xailin OTC eye drop brands and dietary supplements CoQUN and VISUfly.
HBW Insight - April 15, 2026
Japan’s Suntory Makes Major OTC Play With Daiichi Sankyo Deal
Suntory is significantly stepping up its presence in Japan's consumer health market with the acquisition of Daiichi Sankyo Healthcare, which operates in categories such as cold & flu, skin care and oral health.
HBW Insight - April 15, 2026
Suntory is significantly stepping up its presence in Japan's consumer health market with the acquisition of Daiichi Sankyo Healthcare, which operates in categories such as cold & flu, skin care and oral health.
HBW Insight - April 15, 2026
EU Beauty Industry Facing First Compliance Deadline For Allergen Labeling
Cosmetic products newly added to the EU market July 31 and afterward must follow the expanded fragrance allergen labeling requirements of Annex III of the EU Cosmetics Regulation.
HBW Insight - April 15, 2026
Cosmetic products newly added to the EU market July 31 and afterward must follow the expanded fragrance allergen labeling requirements of Annex III of the EU Cosmetics Regulation.
HBW Insight - April 15, 2026
France’s Gemme Becomes ALMA
Becoming the latest industry association to adopt a new identity, French generics and biosimilars group Gemme has become ALMA: the alliance des médicaments abordables, or alliance for affordable medicines.
Generics Bulletin - April 15, 2026
Becoming the latest industry association to adopt a new identity, French generics and biosimilars group Gemme has become ALMA: the alliance des médicaments abordables, or alliance for affordable medicines.
Generics Bulletin - April 15, 2026
Mankind And Amneal Launch US Lumigan Generics Despite Valid Patent
AbbVie/Allergan’s Lumigan is now competing with two generic rivals in the US, even though the drug substance patent is still in force.
Generics Bulletin - April 15, 2026
AbbVie/Allergan’s Lumigan is now competing with two generic rivals in the US, even though the drug substance patent is still in force.
Generics Bulletin - April 15, 2026
Samsung Win Protects Early Foothold In US Ustekinumab Market
Samsung Bioepis can continue supplying its Sandoz-partnered ustekinumab biosimilar to Cigna’s Quallent after the Third Circuit denied Johnson & Johnson’s preliminary injunction bid, preserving a major US distribution channel while the underlying contract dispute proceeds.
Generics Bulletin - April 15, 2026
Samsung Bioepis can continue supplying its Sandoz-partnered ustekinumab biosimilar to Cigna’s Quallent after the Third Circuit denied Johnson & Johnson’s preliminary injunction bid, preserving a major US distribution channel while the underlying contract dispute proceeds.
Generics Bulletin - April 15, 2026
Court Keeps Core Copaxone Claims Alive Against Teva
A US court has narrowed Mylan’s Copaxone antitrust case against Teva, dismissing several theories while allowing core claims on alleged exclusionary conduct, including marketing and rebate practices, to proceed under a broader monopolization framework.
Generics Bulletin - April 15, 2026
A US court has narrowed Mylan’s Copaxone antitrust case against Teva, dismissing several theories while allowing core claims on alleged exclusionary conduct, including marketing and rebate practices, to proceed under a broader monopolization framework.
Generics Bulletin - April 15, 2026
Healthtech Start-Ups Set The Tone At BioWales ’26
A “venture builder” in precision mental health biology, a company that has done the heavy lifting for a class III cardiac implantable and a diagnostics innovator addressing care shift realities long before the NHS’s 10-Year Plan was issued were among the start-ups seeking investors at BioWales 2026.
In Vivo - April 15, 2026
A “venture builder” in precision mental health biology, a company that has done the heavy lifting for a class III cardiac implantable and a diagnostics innovator addressing care shift realities long before the NHS’s 10-Year Plan was issued were among the start-ups seeking investors at BioWales 2026.
In Vivo - April 15, 2026
How An Italian Ocular AAV Innovator Is Bucking The Trend In Gene Therapy
AAVantgarde is advancing dual-AAV gene therapies for two inherited retinal diseases, using staged clinical de-risking to build investor and regulatory confidence ahead of key 2026 data readouts.
In Vivo - April 15, 2026
AAVantgarde is advancing dual-AAV gene therapies for two inherited retinal diseases, using staged clinical de-risking to build investor and regulatory confidence ahead of key 2026 data readouts.
In Vivo - April 15, 2026
Rising Leaders: Helping AI Software Enter Healthcare Systems And Markets
Isabel Vincent, market development manager at life sciences software consultancy Firefinch, has seen an explosion in workload as healthcare organizations and healthtech innovators embed new functionalities into businesses processes. Away from that job, she finds time to advise and mentor start-ups.
In Vivo - April 15, 2026
Isabel Vincent, market development manager at life sciences software consultancy Firefinch, has seen an explosion in workload as healthcare organizations and healthtech innovators embed new functionalities into businesses processes. Away from that job, she finds time to advise and mentor start-ups.
In Vivo - April 15, 2026